Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma

H. Gurney, D. Crowther, H. Anderson, D. Murphy, J. Prendiville, M. Ranson, P. Mayor, R. Swindell, C. H. Buckley, V. R. Tindall

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Eighty eight patients with FIGO stage IIb/c (postoperative residual) or III/IV epithelial ovarian cancer were randomised to receive cycles of cyclophophamide (600 mg/m2) with either iproplatin (240 mg/m2), cisplatin (100 mg/m2) or carboplatin (300 mg/m2). A total of six cycles were given at monthly intervals. Patients were well-balanced for major prognostic factors. There was no significant difference in overall response rate (iproplatin arm, 64.3%, cisplatin arm 72.7% and carboplatin arm 66.7%). There were more complete remissions on the carboplatin arm, 45.8% compared with 21.4% on iproplatin and 22.7% on cisplatin but the difference was not statistically significant (p = 0.11). With a median follow up of 50 months the median survival for the iproplatin arm is 18 months, for the cisplatin arm 19 months and for the carboplatin arm 24 months (p = 0.15). Toxicity was greatest with cisplatin and least with carboplatin. Myelotoxicity limited the dose delivery of iproplatin as measured by total dose, dose intensity and dose intensity product. Carboplatin is at least as effective and less toxic than cisplatin when used in conjunction with cyclophosphamide for the treatment of ovarian carcinoma, and this analogue has been selected for dose intensification studies in this tumour at the Christie Hospital.

LanguageEnglish
Pages427-433
Number of pages7
JournalAnnals of Oncology
Volume1
Issue number6
Publication statusPublished - Nov 1990
Externally publishedYes

Fingerprint

Carboplatin
Cyclophosphamide
Cisplatin
Carcinoma
Poisons
iproplatin
Survival
Neoplasms

Keywords

  • Carboplatin
  • CHIP
  • Cisplatin
  • Ovarian carcinoma

Cite this

Gurney, H. ; Crowther, D. ; Anderson, H. ; Murphy, D. ; Prendiville, J. ; Ranson, M. ; Mayor, P. ; Swindell, R. ; Buckley, C. H. ; Tindall, V. R. / Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. In: Annals of Oncology. 1990 ; Vol. 1, No. 6. pp. 427-433.
@article{e49a77a2d88f4e729f69edd71c33ae47,
title = "Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma",
abstract = "Eighty eight patients with FIGO stage IIb/c (postoperative residual) or III/IV epithelial ovarian cancer were randomised to receive cycles of cyclophophamide (600 mg/m2) with either iproplatin (240 mg/m2), cisplatin (100 mg/m2) or carboplatin (300 mg/m2). A total of six cycles were given at monthly intervals. Patients were well-balanced for major prognostic factors. There was no significant difference in overall response rate (iproplatin arm, 64.3{\%}, cisplatin arm 72.7{\%} and carboplatin arm 66.7{\%}). There were more complete remissions on the carboplatin arm, 45.8{\%} compared with 21.4{\%} on iproplatin and 22.7{\%} on cisplatin but the difference was not statistically significant (p = 0.11). With a median follow up of 50 months the median survival for the iproplatin arm is 18 months, for the cisplatin arm 19 months and for the carboplatin arm 24 months (p = 0.15). Toxicity was greatest with cisplatin and least with carboplatin. Myelotoxicity limited the dose delivery of iproplatin as measured by total dose, dose intensity and dose intensity product. Carboplatin is at least as effective and less toxic than cisplatin when used in conjunction with cyclophosphamide for the treatment of ovarian carcinoma, and this analogue has been selected for dose intensification studies in this tumour at the Christie Hospital.",
keywords = "Carboplatin, CHIP, Cisplatin, Ovarian carcinoma",
author = "H. Gurney and D. Crowther and H. Anderson and D. Murphy and J. Prendiville and M. Ranson and P. Mayor and R. Swindell and Buckley, {C. H.} and Tindall, {V. R.}",
year = "1990",
month = "11",
language = "English",
volume = "1",
pages = "427--433",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "OXFORD UNIV PRESS INC",
number = "6",

}

Gurney, H, Crowther, D, Anderson, H, Murphy, D, Prendiville, J, Ranson, M, Mayor, P, Swindell, R, Buckley, CH & Tindall, VR 1990, 'Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma', Annals of Oncology, vol. 1, no. 6, pp. 427-433.

Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. / Gurney, H.; Crowther, D.; Anderson, H.; Murphy, D.; Prendiville, J.; Ranson, M.; Mayor, P.; Swindell, R.; Buckley, C. H.; Tindall, V. R.

In: Annals of Oncology, Vol. 1, No. 6, 11.1990, p. 427-433.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma

AU - Gurney, H.

AU - Crowther, D.

AU - Anderson, H.

AU - Murphy, D.

AU - Prendiville, J.

AU - Ranson, M.

AU - Mayor, P.

AU - Swindell, R.

AU - Buckley, C. H.

AU - Tindall, V. R.

PY - 1990/11

Y1 - 1990/11

N2 - Eighty eight patients with FIGO stage IIb/c (postoperative residual) or III/IV epithelial ovarian cancer were randomised to receive cycles of cyclophophamide (600 mg/m2) with either iproplatin (240 mg/m2), cisplatin (100 mg/m2) or carboplatin (300 mg/m2). A total of six cycles were given at monthly intervals. Patients were well-balanced for major prognostic factors. There was no significant difference in overall response rate (iproplatin arm, 64.3%, cisplatin arm 72.7% and carboplatin arm 66.7%). There were more complete remissions on the carboplatin arm, 45.8% compared with 21.4% on iproplatin and 22.7% on cisplatin but the difference was not statistically significant (p = 0.11). With a median follow up of 50 months the median survival for the iproplatin arm is 18 months, for the cisplatin arm 19 months and for the carboplatin arm 24 months (p = 0.15). Toxicity was greatest with cisplatin and least with carboplatin. Myelotoxicity limited the dose delivery of iproplatin as measured by total dose, dose intensity and dose intensity product. Carboplatin is at least as effective and less toxic than cisplatin when used in conjunction with cyclophosphamide for the treatment of ovarian carcinoma, and this analogue has been selected for dose intensification studies in this tumour at the Christie Hospital.

AB - Eighty eight patients with FIGO stage IIb/c (postoperative residual) or III/IV epithelial ovarian cancer were randomised to receive cycles of cyclophophamide (600 mg/m2) with either iproplatin (240 mg/m2), cisplatin (100 mg/m2) or carboplatin (300 mg/m2). A total of six cycles were given at monthly intervals. Patients were well-balanced for major prognostic factors. There was no significant difference in overall response rate (iproplatin arm, 64.3%, cisplatin arm 72.7% and carboplatin arm 66.7%). There were more complete remissions on the carboplatin arm, 45.8% compared with 21.4% on iproplatin and 22.7% on cisplatin but the difference was not statistically significant (p = 0.11). With a median follow up of 50 months the median survival for the iproplatin arm is 18 months, for the cisplatin arm 19 months and for the carboplatin arm 24 months (p = 0.15). Toxicity was greatest with cisplatin and least with carboplatin. Myelotoxicity limited the dose delivery of iproplatin as measured by total dose, dose intensity and dose intensity product. Carboplatin is at least as effective and less toxic than cisplatin when used in conjunction with cyclophosphamide for the treatment of ovarian carcinoma, and this analogue has been selected for dose intensification studies in this tumour at the Christie Hospital.

KW - Carboplatin

KW - CHIP

KW - Cisplatin

KW - Ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0025132371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/record.url?scp=77956889914&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 427

EP - 433

JO - Annals of Oncology

T2 - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -